DK3597649T3 - Sammensætninger indeholdende substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer - Google Patents

Sammensætninger indeholdende substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer Download PDF

Info

Publication number
DK3597649T3
DK3597649T3 DK19194930.4T DK19194930T DK3597649T3 DK 3597649 T3 DK3597649 T3 DK 3597649T3 DK 19194930 T DK19194930 T DK 19194930T DK 3597649 T3 DK3597649 T3 DK 3597649T3
Authority
DK
Denmark
Prior art keywords
triazolo
pyrimidin
compounds
compositions containing
containing substituted
Prior art date
Application number
DK19194930.4T
Other languages
English (en)
Inventor
James Breitenbucher
Graeme Freestone
Laurent Gomez
Robert Lemus
Kiev Ly
Margaret Mccarrick
William Vernier
Troy Vickers
Original Assignee
Dart Neuroscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Llc filed Critical Dart Neuroscience Llc
Application granted granted Critical
Publication of DK3597649T3 publication Critical patent/DK3597649T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK19194930.4T 2014-04-23 2015-04-22 Sammensætninger indeholdende substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer DK3597649T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983387P 2014-04-23 2014-04-23
EP15721086.5A EP3134413B1 (en) 2014-04-23 2015-04-22 Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors

Publications (1)

Publication Number Publication Date
DK3597649T3 true DK3597649T3 (da) 2022-01-10

Family

ID=53055118

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15721086.5T DK3134413T3 (da) 2014-04-23 2015-04-22 Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
DK19194930.4T DK3597649T3 (da) 2014-04-23 2015-04-22 Sammensætninger indeholdende substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15721086.5T DK3134413T3 (da) 2014-04-23 2015-04-22 Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer

Country Status (23)

Country Link
US (4) US9932345B2 (da)
EP (2) EP3134413B1 (da)
JP (1) JP6626449B2 (da)
KR (1) KR102471058B1 (da)
CN (2) CN106459062A (da)
AU (2) AU2015249753B2 (da)
BR (1) BR112016024713B1 (da)
CA (1) CA2938294C (da)
DK (2) DK3134413T3 (da)
ES (2) ES2759246T3 (da)
HR (1) HRP20212035T1 (da)
HU (1) HUE057317T2 (da)
IL (2) IL248292A (da)
MA (1) MA50375A (da)
MX (1) MX358004B (da)
NZ (1) NZ725161A (da)
PL (1) PL3597649T3 (da)
PT (1) PT3597649T (da)
RU (1) RU2659070C9 (da)
SG (1) SG11201606216UA (da)
SI (1) SI3597649T1 (da)
TW (1) TWI664181B (da)
WO (1) WO2015164508A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50375A (fr) 2014-04-23 2021-05-26 Dart Neuroscience Cayman Ltd Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2
MA53944A (fr) 2014-08-28 2021-08-25 Asceneuron Sa Inhibiteurs de la glycosidase
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學(開曼)有限責任公司 作為pde2抑制劑之經取代的5-甲基-[1,2,4]三唑并[1,5-a]嘧啶-2-胺化合物
BR112018008431A2 (pt) * 2015-11-02 2018-11-06 Janssen Pharmaceutica Nv composto de [1,2,4]triazolo[1,5-a]pirimidin-7-il
EP3419971B1 (en) 2016-02-25 2022-04-20 Asceneuron SA Glycosidase inhibitors
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
MA43680A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
AU2017222962B2 (en) 2016-02-25 2021-03-25 Asceneuron S. A. Acid addition salts of piperazine derivatives
SG11201903892UA (en) * 2016-11-02 2019-05-30 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
ES2855032T3 (es) 2016-11-02 2021-09-23 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
AU2017353313C1 (en) * 2016-11-02 2022-06-09 Janssen Pharmaceutica Nv (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors
EP3555094A1 (en) * 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Bicyclic oga inhibitor compounds
WO2018154133A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
US11814734B2 (en) 2019-05-13 2023-11-14 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
TW202220992A (zh) 2020-08-05 2022-06-01 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔1,5-a〕嘧啶衍生物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510111A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5478825A (en) 1991-02-22 1995-12-26 Egis Gyogyszergyar 5-(substituted amino)-1,2,4-triazolo (1,5-A) pyrimidine derivatives
HU208693B (en) 1991-02-22 1993-12-28 Egyt Gyogyszervegyeszeti Gyar Process for producing 1,2,4-triazolo (1,5-a) pyrimidinis derivatives and their carbicycli-tetrahydro-thiofurane-tetrahydrothiopyrane-, or tetrahydropyridine- condensated derivatives or medical preparatives containing them
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
WO2002013867A2 (en) 2000-08-10 2002-02-21 Cold Spring Harbor Laboratory Augmented cognitive training
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
WO2002064211A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
FR2832711B1 (fr) * 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
AU2003276220A1 (en) 2002-11-13 2004-06-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)
EP1644003A1 (en) 2003-06-04 2006-04-12 Vernalis (Cambridge) Limited Triazolo ´1,5-a!pyrimidines and their use in medicine
WO2005041957A1 (en) 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
CA2578368C (en) 2004-09-02 2013-07-02 Altana Pharma Ag Triazolophthalazines
BRPI0606379A2 (pt) 2005-01-05 2009-06-23 Nycomed Gmbh triazolftalazinas
US7671050B2 (en) 2005-01-05 2010-03-02 Nycomed Gmbh Triazolophthalazines
US7868016B2 (en) 2005-07-13 2011-01-11 Baxter International Inc. Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
CN101321758A (zh) * 2005-10-03 2008-12-10 阿斯利康(瑞典)有限公司 用于治疗哮喘和慢性阻塞性肺病的新5,6-二氢吡唑并[3,4-e][1,4]二氮杂-4(1H)-酮衍生物
KR100844125B1 (ko) 2007-03-23 2008-07-04 한국화학연구원 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-a]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
CN102014928A (zh) 2007-05-15 2011-04-13 海利空医疗公司 使用小干扰RNA(siRNA)鉴别参与记忆形成的基因的方法
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物
WO2010054253A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Triazine derivatives as inhibitors of phosphodiesterases
WO2010054260A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
NZ594567A (en) 2009-03-31 2013-12-20 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
EP2456440B1 (en) 2009-07-22 2015-08-19 Merck Sharp & Dohme Corp. Quinolinone pde2 inhibitors
EP2651405A2 (en) * 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
CA2825699A1 (en) 2011-02-23 2012-08-30 Thomas Allen Chappie Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
MX2013014470A (es) 2011-06-07 2014-03-21 Pfizer Compuestos de pirazolo[3,4-d]pirimidina y su uso como inhibidores pde2 y/o inhibidores cyp3a4.
MX344600B (es) 2011-06-27 2016-12-20 Janssen Pharmaceutica Nv Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina.
WO2013034755A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders
WO2013034758A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Substituted triazolopyrazines and uses thereof
WO2013034761A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Pyridine compounds and uses thereof
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
CN103183675A (zh) * 2011-12-27 2013-07-03 山东轩竹医药科技有限公司 磷酸二酯酶-4抑制剂
US20160159808A1 (en) 2013-07-24 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compound
MA50375A (fr) 2014-04-23 2021-05-26 Dart Neuroscience Cayman Ltd Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學(開曼)有限責任公司 作為pde2抑制劑之經取代的5-甲基-[1,2,4]三唑并[1,5-a]嘧啶-2-胺化合物

Also Published As

Publication number Publication date
US20170057967A1 (en) 2017-03-02
CN110092788B (zh) 2022-02-25
AU2015249753A1 (en) 2016-11-03
IL254224A0 (en) 2017-10-31
KR20160145745A (ko) 2016-12-20
CN106459062A (zh) 2017-02-22
HUE057317T2 (hu) 2022-04-28
IL248292A (en) 2017-09-28
EP3134413A1 (en) 2017-03-01
EP3597649B1 (en) 2021-10-13
KR102471058B1 (ko) 2022-11-25
ES2902806T3 (es) 2022-03-29
CN110092788A (zh) 2019-08-06
PT3597649T (pt) 2022-01-21
US10501465B2 (en) 2019-12-10
PL3597649T3 (pl) 2022-04-04
EP3134413B1 (en) 2019-09-11
JP6626449B2 (ja) 2019-12-25
ES2759246T3 (es) 2020-05-08
AU2015249753B2 (en) 2019-10-10
US20180179216A1 (en) 2018-06-28
BR112016024713A2 (pt) 2017-08-15
CA2938294A1 (en) 2015-10-29
TWI664181B (zh) 2019-07-01
US20200095256A1 (en) 2020-03-26
MX358004B (es) 2018-07-31
RU2016143387A (ru) 2018-05-23
WO2015164508A4 (en) 2015-12-23
HRP20212035T1 (hr) 2022-04-01
BR112016024713B1 (pt) 2023-05-02
AU2019283994B2 (en) 2021-05-27
RU2016143387A3 (da) 2018-05-23
NZ725161A (en) 2017-10-27
RU2659070C9 (ru) 2018-08-24
US11186582B2 (en) 2021-11-30
US9932345B2 (en) 2018-04-03
AU2019283994A1 (en) 2020-01-23
DK3134413T3 (da) 2019-10-14
AU2019283994C1 (en) 2021-12-09
MX2016013860A (es) 2017-05-12
SG11201606216UA (en) 2016-09-29
US20230192698A1 (en) 2023-06-22
MA50375A (fr) 2021-05-26
RU2659070C2 (ru) 2018-06-28
EP3597649A1 (en) 2020-01-22
SI3597649T1 (sl) 2022-04-29
TW201625625A (zh) 2016-07-16
WO2015164508A1 (en) 2015-10-29
EP3597649B8 (en) 2022-02-16
CA2938294C (en) 2023-02-21
IL254224B (en) 2019-01-31
JP2017513808A (ja) 2017-06-01

Similar Documents

Publication Publication Date Title
DK3597649T3 (da) Sammensætninger indeholdende substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
IL276908A (en) Use of pyrrolopyrimidine compounds as an agonist for TLR7
DK3322706T3 (da) Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
DK3523301T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3523302T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
HK1256751A1 (zh) [1,2,4]三唑並[1,5-a]嘧啶-7-基化合物
DK3419978T3 (da) Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
DK3077397T3 (da) 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
EP3337787A4 (en) HETEROCYCLIC PYRAZOLO COMPOUNDS CONDENSED AS ERK INHIBITORS
EP3328840A4 (en) TRIAZOLO BICYCLIC COMPOUNDS SUBSTITUTED AS PDE2 INHIBITORS
EP3319966A4 (en) BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS
EP3302484A4 (en) 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
EP3313852A4 (en) Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
DK3679042T3 (da) Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
EP3302486A4 (en) Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
DK3194408T3 (da) Tetrahydropyrrolo[3,4-d][1,3]thiazin-derivat som bace-inhibitor
EP3291817A4 (en) Heteroaryl-pyrimidinone compounds as pde2 inhibitors
HK1244277A1 (zh) 新的取代的三唑並嘧啶作為抗瘧藥
TH1601003657A (th) อนุพันธ์ [1,2,4] ไตรอะโซโล [1,5-a]ไพริมิดีน ดังสารยับยั้งโปรเตียโซมของ โปรโตซัวสำหรับการรักษาของโรคที่เกิดจากปรสิต เช่น โรคลิชมาเนียซิส
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่